ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01257074
Recruitment Status : Completed
First Posted : December 9, 2010
Last Update Posted : March 4, 2013
Sponsor:
Information provided by (Responsible Party):
EMS

Brief Summary:
Herpes labialis is the most common recurrent manifestation of herpes simplex. The purpose of this study is to check the non-inferiority efficacy and safety of penciclovir 10mg/g as treatment for Herpes Labialis in comparison to acyclovir 50mg/g.

Condition or disease Intervention/treatment Phase
Herpes Labialis Drug: Acyclovir 50mg/g Drug: Penciclovir 10mg/g Phase 3

Detailed Description:

Study design:

• Double blinded non-inferiority prospective parallel-group, intend to treat trial.

Study design:

  • Experiment duration: 10 days
  • 3 visits (days 1,5 and 10)
  • Erythema, papule, vesicle, ulcer, crust and healed skin evaluation
  • Adverse events evaluation

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, to Compare Non-inferiority Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis.
Study Start Date : February 2012
Actual Primary Completion Date : March 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cold Sores

Arm Intervention/treatment
Experimental: Drug 1
Penciclovir 10mg/g
Drug: Penciclovir 10mg/g
Cream, dose 5 times daily during 5 days

Active Comparator: Drug 2
Acyclovir 50mg/g
Drug: Acyclovir 50mg/g
Cream, dose 5 times daily during 5 days




Primary Outcome Measures :
  1. Efficacy will be evaluated by the proportion of subjects with non herpes labialis manifestation [ Time Frame: Day 10 ]
    Symptoms evaluated: erythema, papule, vesicle, ulcer, crust, or healed skin.


Secondary Outcome Measures :
  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Day 10 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must be able to understand the study procedures agree to participate and give written consent.
  2. Patients with clinical diagnosis of recurrent herpes labialis and are in the prodromal period (stinging, itching, burning and erythema) at the onset of signs / symptoms in the last 12-24 hours;
  3. No history of reaction to topical products;

Exclusion Criteria:

  1. Pregnancy or risk of pregnancy.
  2. Lactation
  3. Use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study.)
  4. Sunlight over exposure in the last 15 days.
  5. Any pathology or past medical condition that can interfere with this protocol.
  6. AINH use, hormonal anti-inflammatory, analgesic and immunosuppressive drugs (in the last 30 days and during the study);
  7. Patients with immunodeficiency and/or immunosuppressive disease;
  8. Sunlight exposure in the last 15 days;
  9. Hypersensitivity to components of the formula;
  10. Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01257074


Locations
Brazil
Flavia Addor
São Paulo, Brazil
Sponsors and Collaborators
EMS
Investigators
Principal Investigator: Flavia Addor, MD Medcin Instituto da Pele Ltda

Responsible Party: EMS
ClinicalTrials.gov Identifier: NCT01257074     History of Changes
Other Study ID Numbers: PENEMS1010
First Posted: December 9, 2010    Key Record Dates
Last Update Posted: March 4, 2013
Last Verified: March 2013

Keywords provided by EMS:
Herpes Simplex

Additional relevant MeSH terms:
Herpes Labialis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Lip Diseases
Mouth Diseases
Stomatognathic Diseases
Skin Diseases, Infectious
Skin Diseases
Acyclovir
Penciclovir
Antiviral Agents
Anti-Infective Agents